Last updated: February 1, 2022
Sponsor: N/A
Overall Status: Active - Recruiting
Phase
N/A
Condition
Parkinson's Disease
Treatment
N/AClinical Study ID
TX224549
Ages 40-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion:
- Diagnosis of PD made according to UK Parkinson’s Disease Society Brain Bank Criteria;
- Ability to provide written informed consent;
- Age 40-75;
- Stable dose of antiparkinsonian medication for >1 month prior to study entry.
Exclusion:
- Subjects with pathogenic mutations in LRRK2;
- History of known causative factors such as encephalitis or neuroleptic treatment;
- Patients with dementia (defined as a Mini-Mental Status Exam score <24 or a Telephone Interview for Cognitive Status score <26);
- Atypical parkinsonian features including myoclonus, apraxia, oculomotor abnormalities, incontinence, ataxia, sensory loss, or pyramidal signs;
- Known structural brain lesions;
- Patients with a history of stroke, head injury, high intracranial pressure or severe headaches;
- Psychiatric disorder, including a history of major depression in the past 36 months;
- Pregnant or breastfeeding women (female subjects of child-bearing potential will be screened for pregnancy before imaging).
Study Design
Study Start date:
Estimated Completion Date:
Study Description
Connect with a study center
Northwell Office of Clinical Research
Lake Success, New York 11042
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.